To date, there are eight genes that constitute well-defined targets of Food and Drug Administration (FDA)-approved drugs: EGFR, KRAS, ALK, MET, ROS1, BRAF, RET, and NTRK. While the distribution of genomic alterations in NSCLC is described in prior reports, most have focused on one alteration [3, 4], one histology [5], or a single race [6, 7]. This evidence concerns the gene ALK and non-small cell lung carcinoma.